title: Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.
abstract: Intra-arterial therapies (IATs) play a pivotal role in the management of patients with primary and secondary liver malignancies. The unique advantages of these treatments are their ability to selectively deliver a high dose of anticancer treatment while preserving healthy liver tissue. The proven efficacy of these catheter-based locoregional therapies in a highly systemic chemoresistant cancer such as hepatocellular carcinoma (HCC), along with the minimally invasive nature of these treatments, quickly yielded wide acceptance in the medical community and revolutionized the field of Interventional Oncology. In this article, we describe the clinical rationale and background of catheter-based IATs. We provide an overview of clinical achievements of these treatments alone and in combination with sorafenib in patients with HCC.
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Baltimore, MD, USA.
authors.forename: R
authors.initials: R
authors.lastname: Duran
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Baltimore, MD, USA.
authors.forename: J
authors.initials: J
authors.lastname: Chapiro
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Baltimore, MD, USA.
authors.forename: R E
authors.initials: RE
authors.lastname: Schernthaner
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Division of Vascular and Interventional Radiology, The Johns Hopkins Hospital, Baltimore, MD, USA.
authors.forename: J-F H
authors.initials: JF
authors.lastname: Geschwind
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods; D016461:Chemoembolization, Therapeutic / Q000379:methods; D003131:Combined Modality Therapy; D004059:Diffusion of Innovation; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D005544:Forecasting; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008863:Microspheres; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D018579:Patient Selection; D010671:Phenylurea Compounds / Q000008:administration & dosage; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D000077157:Sorafenib; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D009536:Niacinamide; D000077157:Sorafenib